| Drug treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis WJ Canestaro, SH Forrester, G Raghu, L Ho, BE Devine Chest 149 (3), 756-766, 2016 | 219 | 2016 |
| Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review WJ Canestaro, MA Austin, KE Thummel Genetics in Medicine 16 (11), 810-819, 2014 | 89 | 2014 |
| Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation WJ Canestaro, AR Patrick, J Avorn, K Ito, OS Matlin, TA Brennan, ... Circulation: Cardiovascular Quality and Outcomes 6 (6), 724-731, 2013 | 89 | 2013 |
| Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels B Wang, WJ Canestaro, NK Choudhry JAMA internal medicine 174 (12), 1938-1944, 2014 | 57 | 2014 |
| Systematic review: patient‐reported outcome measures in coeliac disease for regulatory submissions WJ Canestaro, TC Edwards, DL Patrick Alimentary Pharmacology & Therapeutics 44 (4), 313-331, 2016 | 39 | 2016 |
| The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib JJ Carlson, W Canestaro, A Ravelo, W Wong Journal of Medical Economics 20 (7), 671-677, 2017 | 32 | 2017 |
| At-Home versus in-clinic INR monitoring: A cost–utility analysis from the home INR study (THINRS) CS Phibbs, SR Love, AK Jacobson, R Edson, P Su, L Uyeda, DB Matchar, ... Journal of general internal medicine 31, 1061-1067, 2016 | 26 | 2016 |
| Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing WJ Canestaro, DG Brooks, D Chaplin, NK Choudhry, E Lawler, L Martell, ... Journal of Personalized Medicine 2 (4), 158-174, 2012 | 24 | 2012 |
| Favorable and publicly funded studies are more likely to be published: a systematic review and meta-analysis WJ Canestaro, N Hendrix, A Bansal, SD Sullivan, EB Devine, JJ Carlson Journal of Clinical Epidemiology 92, 58-68, 2017 | 20 | 2017 |
| Impact of CYP2C19 Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary … NR Desai, WJ Canestaro, P Kyrychenko, D Chaplin, LA Martell, ... Circulation: Cardiovascular Quality and Outcomes 6 (6), 694-699, 2013 | 20 | 2013 |
| Implications of employer coverage of contraception: Cost‐effectiveness analysis of contraception coverage under an employer mandate W Canestaro, E Vodicka, D Downing, J Trussell Contraception 95 (1), 77-89, 2017 | 19 | 2017 |
| Improving the efficiency and quality of the value assessment process for companion diagnostic tests: the Companion test Assessment Tool (CAT) WJ Canestaro, DE Pritchard, LP Garrison, R Dubois, DL Veenstra Journal of Managed Care & Specialty Pharmacy 21 (8), 700-712, 2015 | 14 | 2015 |
| R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life C Scallan, L Strand, J Hayes, S Kadura, B Collins, L Ho, C Spada, ... European Respiratory Journal 59 (1), 2022 | 10 | 2022 |
| Healthcare payers: a gate or translational bridge to personalized medicine? WJ Canestaro, LA Martell, ER Wassman, R Schatzberg Personalized Medicine 9 (1), 73-84, 2012 | 7 | 2012 |
| Characterizing the strength of evidence in FDA labels for pharmacogenomic biomarker-guided medication use L Chin, B Devine, S Baradaran, K Keyloun, W Canestaro, J Pham AMIA Summits on Translational Science Proceedings 2017, 30, 2017 | 2 | 2017 |
| Publication Bias: Assessment and Impact WJ Canestaro | 2 | 2017 |
| Drug therapy for treatment of idiopathic pulmonary fibrosis: a systematic review and network meta-analysis WJ Canestaro, S Forrester, L Ho, B Devine Value in Health 18 (3), A170, 2015 | 2 | 2015 |
| Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment WJ Canestaro, RJ Bateman, DM Holtzman, M Monane, JB Braunstein Population Health Management, 2024 | 1 | 2024 |
| Adjustment of publication bias using a cumulative meta-analytic framework WJ Canestaro, EB Devine, A Bansal, SD Sullivan, JJ Carlson International Journal of Technology Assessment in Health Care 38 (1), e61, 2022 | 1 | 2022 |
| The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. JJ Carlson, WB Wong, W Canestaro Journal of Clinical Oncology 34 (15_suppl), 6610-6610, 2016 | 1 | 2016 |
